UPDATE: Citigroup Upgrades Merck; Raises PT

by Benzinga Staff
July 12, 2012 10:48 AM | 24 seconds read | Make a Comment

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

According to a research report released Thursday, Citigroup has upgraded Merck (NYSE: MRK) from Neutral to Buy, and increased PT from $34 to $50.In the report, Citigroup said, "MRK announced that the Data Monitoring Committee (DMC) stopped its 16,500 patient Ph-III odanacatib (odana) trial early on a “favorable benefit-risk profile” in postmenopausal patients with osteoporosis. MRK expects to submit regulatory applications in the US/EU in 1H13 & Japan in 2H13."Merck was trading up 4.34% from yesterday's $41.21 closing price.

20-Year Pro Trader Reveals His "MoneyLine"

Ditch your indicators and use the "MoneyLine". A simple line tells you when to buy and sell without the guesswork. It’s a line on a chart that’s helped Nic Chahine win 83% of his options buys. Here's how he does it.

ENTER TO WIN $500 IN STOCK OR CRYPTO

Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!

Posted In: Analyst ColorUpgradesAnalyst RatingsCitigroup

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.